Study Phase 4

Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaNervous SystemEnrollment96% Female12.5%% White70%
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRISAUT4002Data PartnerJohnson & JohnsonCondition StudiedAutistic DisorderMean/Median Age (Years)9.3

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.